What does vital drug Creon do – and how is a shortage affecting patients?

An Overview of the Creon Shortage and Its Impact

The Creon shortage has sparked widespread concern among patients who rely on this medication for pancreatic insufficiency. Wes Streeting, the UK’s Health Secretary, has publicly apologized for the distress this situation has caused, acknowledging the significant challenges posed by global supply chain disruptions. He emphasized the anxiety patients face when trying to renew their prescriptions, a sentiment shared by many who depend on this vital medication.

Understanding Creon and Its Role in Health

Creon is a leading brand of pancreatic enzyme replacement therapy (PERT), essential for individuals with exocrine pancreatic insufficiency (EPI). Without adequate enzyme production, the body struggles to digest proteins, fats, and carbohydrates, leading to malnutrition and other complications. Creon and similar medications like Nutrizym and Pancrex provide the necessary enzymes to facilitate proper digestion, often requiring patients to take multiple tablets with each meal. The variability in dosage reflects the diverse needs of patients, who may need up to 15 tablets per meal, as shared by pancreatic cancer patient Dan Godley.

The Causes and Symptoms of EPI

EPI is commonly associated with conditions such as chronic pancreatitis, cystic fibrosis, and pancreatic cancer. Symptoms include diarrhea, abdominal pain, and malnutrition, which can severely impact quality of life and overall health. Left untreated, EPI can lead to nutrient deficiencies, weakened immunity, and increased risks of heart attacks and strokes. For children, growth problems may arise, underscoring the critical need for effective management of this condition.

Addressing the Creon Shortage

The shortage of Creon and other PERT medications is attributed to limited raw materials and production capacity. The UK government, manufacturers, and health organizations are collaborating to resolve these issues. Pancreatic Cancer UK reports estimated shortages until 2026, affecting thousands. Patients have expressed difficulties in accessing their medications, with many resorting to reduced doses or seeking alternative sources, highlighting the urgent need for solutions.

Patient Experiences and Advocacy

Patients and families are deeply affected by the Creon shortage. Michael Harvey, a pancreatic cancer survivor, shares his challenges in obtaining consistent supplies, often facing uncertainty each month. Tony Audenshaw, whose late wife relied on PERT during her illness, emphasizes the medication’s role in maintaining quality of life. Advocacy groups and health organizations are urging swift action to ensure reliable access to these essential drugs.

Manufacturer and Government Responses

Manufacturers like Viatris, Essential Pharma, and Zentiva are working to increase production and distribute available supplies efficiently. The Department of Health and Social Care assures ongoing efforts to strengthen supply chain resilience and explore alternative solutions. While progress is anticipated, the situation remains challenging, necessitating continued collaboration and support to mitigate the impact on patients’ lives.